Literature DB >> 18849890

Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.

Rainald Mössner1, Anna Schuhmacher, Kai-Uwe Kühn, Gabriela Cvetanovska, Dan Rujescu, Peter Zill, Boris B Quednow, Marcella Rietschel, Wolfgang Wölwer, Wolfgang Gaebel, Michael Wagner, Wolfgang Maier.   

Abstract

The serotonin (5-HT) 1A receptor has been found to be dysregulated in prefrontal cortex and other brain regions in schizophrenia, and 5-HT1A receptor levels in the amygdala have been related to negative schizophrenia symptoms. We have assessed the impact of the functional C-1019G variant of the 5-HT1A receptor on the response to risperidone or haloperidol in a prospective, randomized, double-blind study. Patients were treated for 4 weeks and negative symptoms assessed weekly. The variant influenced the response to risperidone: improvement of negative symptoms by 4.38 points for carriers of the C allele, compared with the GG genotype (1.22 points, P=0.046). In a second independent study of 130 schizophrenia patients treated with atypical antipsychotics, this effect was confirmed (P=0.003). The functional variant of the 5-HT1A receptor thus influences the response of schizophrenia patients to atypical antipsychotics and may be useful in the future to predict the pharmacogenetics of negative symptoms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18849890     DOI: 10.1097/FPC.0b013e328311a917

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  17 in total

Review 1.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 2.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

Review 3.  Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.

Authors:  Gavin P Reynolds; Olga O McGowan; Caroline F Dalton
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

4.  The pharmacogenetics of symptom response to antipsychotic drugs.

Authors:  Gavin P Reynolds
Journal:  Psychiatry Investig       Date:  2012-01-09       Impact factor: 2.505

5.  Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics.

Authors:  Concetta Crisafulli; Alberto Chiesa; Changsu Han; Soo-Jung Lee; Moon Ho Park; Beatrice Balzarro; Costanza Andrisano; Ashwin A Patkar; Chi-Un Pae; Alessandro Serretti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-27       Impact factor: 5.270

Review 6.  Epigenetics and biomarkers in the staging of neuropsychiatric disorders.

Authors:  Trevor Archer; Richard J Beninger; Tomas Palomo; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

Review 7.  Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

Authors:  Adrian Newman-Tancredi; Mark S Kleven
Journal:  Psychopharmacology (Berl)       Date:  2011-03-11       Impact factor: 4.530

8.  The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms.

Authors:  Rainald Mössner; Anna Schuhmacher; Michael Wagner; Leonhard Lennertz; Anja Steinbrecher; Boris B Quednow; Dan Rujescu; Marcella Rietschel; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-09-04       Impact factor: 5.270

Review 9.  Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.

Authors:  Pau Celada; Analía Bortolozzi; Francesc Artigas
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

Review 10.  Aripiprazole versus other atypical antipsychotics for schizophrenia.

Authors:  Priya Khanna; Tao Suo; Katja Komossa; Huaixing Ma; Christine Rummel-Kluge; Hany George El-Sayeh; Stefan Leucht; Jun Xia
Journal:  Cochrane Database Syst Rev       Date:  2014-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.